biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
107-1A4, monoclonal
form
buffered aqueous solution
species reactivity
human
packaging
antibody small pack of 25 μL
concentration
~1.0 mg/mL
technique(s)
flow cytometry: suitable, immunocytochemistry: suitable, immunoprecipitation (IP): suitable, indirect ELISA: suitable, indirect immunofluorescence: 5-10 μg/mL using methanol/acetone fixed LNCaP cells.
isotype
IgG1
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... FOLH1(2346)
General description
Monoclonal Anti-PSMA (mouse IgG1 isotype) is derived from the hybridoma 107-1A4 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice. Prostate-specific membrane antigen (PSMA) is an integral, non-shed, type 2 transmembrane glycoprotein belonging to the M28 peptidase family.
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), folate hydrolase 1 (FOLH1), is a 100kDa membrane glycoprotein, composed of 750 amino acids. PSMA gene with 19 exons and 18 introns is mapped to human chromosome 11p11–12. The encoded protein is detected in various type of tissues including kidney, prostate and brain. PSMA contains short cytoplasmic amino terminus, a single membrane-spanning domain and a large extracellular domain.
Immunogen
prostate cancer LNCaP cells.
Application
Monoclonal Anti-PSMA antibody produced in mouse has been used in:
- enzyme linked immuno sorbent assay (ELISA)
- immunocytochemistry
- immunoprecipitation
- flow cytometry
Biochem/physiol Actions
Prostate-specific membrane antigen (PSMA), expressed in the brain, catalyzes the hydrolysis of N-acetyl-aspartyl glutamate to produce free glutamate. Elevated expression of the protein is associated with the development of prostate tumor. Mutations in PSMA leads to hyperhomocysteinemia. PSMA functions as a potential biomarker of prostate adenocarcinoma.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
低风险生物材料
常规特殊物品
常规特殊物品
此项目有
Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia
Devlin AM
Human Molecular Genetics, 9, 2837-2844 (2000)
Benedikt Kranzbühler et al.
The Prostate, 79(12), 1450-1456 (2019-06-25)
Prostate-specific membrane antigen (PSMA)-based imaging and therapy are increasingly used in the management of prostate cancer. However, low PSMA surface expression in certain patients is a limitation for PSMA-based technologies. We have previously shown that high doses of dutasteride, a
Investigational antibody drug conjugates for solid tumors
Sapra P, et al.
Expert Opinion on Investigational Drugs, 20(8), 1131-1149 (2011)
Construction of Prostate-Specific Expressed Recombinant Plasmids With High Transcriptional Activity of Prostate-Specific Membrane Antigen (PSMA) Promoter/Enhancer
Zeng H
Journal of Andrology, 26, 215-221 (2005)
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Ghosh A and Heston WD
Journal of Cellular Biochemistry, 91, 528-539 (2004)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持